AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26

Authors: Danesi, R De Braud, F Fogli, S Di Paolo, A Del Tacca, M
Citation: R. Danesi et al., Pharmacogenetic determinants of anti-cancer drug activity and toxicity, TRENDS PHAR, 22(8), 2001, pp. 420-426

Authors: Bocci, G Fasciani, A Danesi, R Viacava, P Genazzani, AR Del Tacca, M
Citation: G. Bocci et al., In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels, MOL HUM REP, 7(8), 2001, pp. 771-777

Authors: Di Paolo, A Danesi, R Falcone, A Cionini, L Vannozzi, F Masi, G Allegrini, G Mini, E Bocci, G Conte, PF Del Tacca, M
Citation: A. Di Paolo et al., Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients, ANN ONCOL, 12(9), 2001, pp. 1301-1306

Authors: Fogli, S Danesi, R Braud, FD Pas, TD Curigliano, G Giovannetti, E Del Tacca, M
Citation: S. Fogli et al., Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer, ANN ONCOL, 12(11), 2001, pp. 1553-1559

Authors: Bengala, C Pazzagli, I Innocenti, F Donati, S Favre, C Menconi, MC Greco, F Danesi, R Orlandini, C Guarneri, V Del Tacca, M Conte, PF
Citation: C. Bengala et al., High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC), ANN ONCOL, 12(1), 2001, pp. 69-74

Authors: Falcone, A Di Paolo, A Masi, G Allegrini, G Danesi, R Lencioni, M Pfanner, E Comis, S Del Tacca, M Conte, P
Citation: A. Falcone et al., Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients, J CL ONCOL, 19(15), 2001, pp. 3456-3462

Authors: Conte, PF Gennari, A Donati, S Salvadori, B Baldini, E Bengala, C Pazzagli, I Orlandini, C Danesi, R Fogli, S Del Tacca, M
Citation: Pf. Conte et al., Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study, BREAST CANC, 68(2), 2001, pp. 171-179

Authors: Falcone, A Allegrini, G Masi, G Lencioni, M Pfanner, E Brunetti, I Danesi, R Bocci, G Del Tacca, M Conte, P
Citation: A. Falcone et al., 5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer, ONCOL-BASEL, 61(1), 2001, pp. 28-35

Authors: Macchia, M Barontini, S Bertini, S Di Bussolo, V Fogli, S Giovannetti, E Grossi, E Minutolo, F Danesi, R
Citation: M. Macchia et al., Design, synthesis, and characterization of the antitumor activity of novelceramide analogues, J MED CHEM, 44(23), 2001, pp. 3994-4000

Authors: Di Paolo, A Danesi, R Caputo, S Macchia, M Lastella, M Boggi, U Mosca, F Marchetti, A Del Tacca, M
Citation: A. Di Paolo et al., Inhibition of protein farnesylation enhances the chemotherapeutic efficacyof the novel geranylgeranyltransferase inhibitor BAL9611 colon cancer cells, BR J CANC, 84(11), 2001, pp. 1535-1543

Authors: Danesi, R Mosca, M Boggi, U Mosca, F Del Tacca, M
Citation: R. Danesi et al., Genetics of drug response to immunosuppressive treatment and prospects forpersonalized therapy, MOL MED TOD, 6(12), 2000, pp. 475-482

Authors: Bocci, G Danesi, R Di Paolo, A Innocenti, F Allegrini, G Falcone, A Melosi, A Battistoni, M Barsanti, G Conte, PF Del Tacca, M
Citation: G. Bocci et al., Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients, CLIN CANC R, 6(8), 2000, pp. 3032-3037

Authors: De Pas, T de Braud, F Danesi, R Sessa, C Catania, C Curigliano, G Fogli, S del Tacca, M Zampino, G Sbanotto, A Rocca, A Cinieri, S Marrocco, E Milani, A Goldhirsch, A
Citation: T. De Pas et al., Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer, ANN ONCOL, 11(7), 2000, pp. 821-827

Authors: Collecchi, P Santoni, T Gnesi, E Naccarato, AG Passoni, A Rocchetta, M Danesi, R Bevilacqua, G
Citation: P. Collecchi et al., Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas, CYTOMETRY, 42(4), 2000, pp. 254-260

Authors: Innocenti, F Danesi, R Favre, C Nardi, M Menconi, MC Di Paolo, A Bocci, G Fogli, S Barbara, C Barachini, S Casazza, G Macchia, P Del Tacca, M
Citation: F. Innocenti et al., Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: Implications for drug monitoring in children withacute lymphoblastic leukemia, THER DRUG M, 22(4), 2000, pp. 375-382

Authors: Gennari, A Donati, S Danesi, R Fogli, S Orlandini, C Del Tacca, M Conte, PF
Citation: A. Gennari et al., The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer, SEMIN ONCOL, 27(1), 2000, pp. 14-19

Authors: Basolo, F Fiore, L Baldanzi, A Giannini, R Dell'Omodarme, M Fontanini, G Pacini, F Danesi, R Miccoli, P Toniolo, A
Citation: F. Basolo et al., Suppression of Fas expression and down-regulation of Fas ligand in highly aggressive human thyroid carcinoma, LAB INV, 80(9), 2000, pp. 1413-1419

Authors: Di Paolo, A Danesi, R Nardini, D Bocci, G Innocenti, F Fogli, S Barachini, S Marchetti, A Bevilacqua, G Del Tacca, M
Citation: A. Di Paolo et al., Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells, BR J CANC, 82(4), 2000, pp. 905-912

Authors: Gennari, A Salvadori, B Donati, S Bengala, C Orlandini, C Danesi, R Del Tacca, M Bruzzi, P Conte, PF
Citation: A. Gennari et al., Cardiotoxicity of epirubicin/paclitaxel-containing regimens: Role of cardiac risk factors, J CL ONCOL, 17(11), 1999, pp. 3596-3602

Authors: Innocenti, F Danesi, R Bocci, G Fogli, S Di Paolo, A Del Tacca, M
Citation: F. Innocenti et al., Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens, CANC CHEMOT, 43(2), 1999, pp. 133-140

Authors: Danesi, R Conte, PF Del Tacca, M
Citation: R. Danesi et al., Pharmacokinetic optimisation of treatment schedules for anthracyclines andpaclitaxel in patients with cancer, CLIN PHARMA, 37(3), 1999, pp. 195-211

Authors: Del Tacca, M Di Paolo, A Danesi, R
Citation: M. Del Tacca et al., Clinical and preclinical pharmacology of Topotecan, TUMORI, 85(6), 1999, pp. S3-S11

Authors: Fogli, S Danesi, R Innocenti, F Di Paolo, A Bocci, G Barbara, C Del Tacca, M
Citation: S. Fogli et al., An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma, THER DRUG M, 21(3), 1999, pp. 367-375

Authors: Falcone, A Allegrini, G Antonuzzo, A Brunetti, I Pfanner, E Lencioni, M Masi, G Danesi, R Del Tacca, M Conte, P
Citation: A. Falcone et al., Infusions of fluorouracil and leucovorin: Effects of the timing and semi-intermittency of drug delivery, ONCOL-BASEL, 57(3), 1999, pp. 195-201

Authors: Falcone, A Antonuzzo, A Danesi, R Allegrini, G Monica, L Pfanner, E Masi, G Ricci, S Del Tacca, M Conte, P
Citation: A. Falcone et al., Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma, CANCER, 86(3), 1999, pp. 470-476
Risultati: 1-25 | 26-26